Hemodynamics, fluids & transfusion
Angiotensin II, conventional vasopressor therapy, and mortality in shock: a large, multicenter, propensity score-weighted analysis
Authors' conclusion
Ang II administration was associated with a lower risk of death in unadjusted and adjusted analyses. This effect was preserved only with patients receiving NE at doses ranging from 0.4 to 0.6 mcg/kg/min.
Study context
- Population
- Patients receiving vasopressors for shock at four centers in a single healthcare system
- Participants
- 811 patients · 4 centers
- Exposure
- Ang II plus conventional therapy vs conventional therapy alone
- Ang IIn = 275
- Conventional therapyn = 536reference
- Outcome
- Mortality
- Follow-up
- 30 days
Methodological detailspropensity score inverse probability of treatment weighting, multicentre
- Propensity score inverse probability of treatment weighting
- Multicentre
Main finding
As reported in the abstract
Ang II vs Conventional therapyOdds ratio (95% CI)P value
Multivariable logistic regression
0.65(0.45–0.95)
P = 0.025After IPTW
0.74(0.55–0.99)
P = 0.040- Overall 30-day mortality
- 56.4%
Observational data: associations, not effects.
Further findings
30-day mortality by background norepinephrine equivalent (NE) dose (subgroup)
- Lower mortality with Ang II at background NE doses > 0.4, > 0.5, and ≤ 0.6 mcg/kg/min
- Not significantly associated with mortality at background NE dose > 0.6
Original publication
Angiotensin II, conventional vasopressor therapy, and mortality in shock: a large, multicenter, propensity score-weighted analysis. Ann Intensive Care. Published 23 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →